Recent Company News

• 04:21 PM ET Oct 08, 2026
  

  Tenax Therapeutics discloses plans to amend enrollment criteria in LEVEL-2 trial; temporarily pauses enrollment - 8-K ($1.86, 0.00)

• 04:14 AM ET Oct 06, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:54 AM ET Oct 06, 2026
  

  StreetAccount Summary - European pre-market trading update

• 02:05 AM ET Oct 06, 2026
  

  Orion announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market (€80.85, 0.00)

• 08:01 AM ET Oct 05, 2026
  

  Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216 (€81.60, +0.80)

• 02:17 AM ET Sep 30, 2026
  

  Orion Corporation completes buyback (€82.40, 0.00)

• 04:04 AM ET Sep 28, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (91 total)

• 04:23 AM ET Sep 22, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (84 total)

• 07:18 AM ET Aug 10, 2026
  

  Orion notes license partner Tenax Therapeutics' Phase 3 LEVEL trial of oral levosimendan in PH-HFpEF did not reach its primary endpoint (€79.25, -2.25)

• 04:02 AM ET Aug 07, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (49 total)